Immunomedics (IMMU) Reaches New 12-Month High at $14.57

Immunomedics, Inc. (NASDAQ:IMMU) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $14.57 and last traded at $14.49, with a volume of 1658207 shares changing hands. The stock had previously closed at $13.81.

A number of research firms have issued reports on IMMU. ValuEngine lowered Immunomedics from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. Zacks Investment Research raised Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, October 4th. Jefferies Group raised their target price on Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Finally, BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Immunomedics presently has an average rating of “Buy” and a consensus price target of $15.33.

The stock has a market cap of $2,099.41, a PE ratio of -6.57 and a beta of 1.51. The company has a quick ratio of 0.74, a current ratio of 0.74 and a debt-to-equity ratio of -0.29.

In other Immunomedics news, Director Brian A. Markison sold 8,390 shares of Immunomedics stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the transaction, the director now owns 99,178 shares of the company’s stock, valued at $1,179,226.42. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Venbio Select Advisor Llc bought 1,150,000 shares of the stock in a transaction on Tuesday, November 14th. The stock was bought at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The disclosure for this purchase can be found here. Insiders own 6.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its stake in shares of Immunomedics by 8.1% in the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 966 shares in the last quarter. Stephens Inc. AR purchased a new stake in Immunomedics during the second quarter worth $115,000. Raymond James Financial Services Advisors Inc. boosted its position in Immunomedics by 11.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,473 shares in the last quarter. SG Americas Securities LLC boosted its position in Immunomedics by 99.3% during the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 10,323 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Immunomedics by 38.8% during the first quarter. Bank of America Corp DE now owns 33,707 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 9,426 shares in the last quarter. Institutional investors own 76.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Immunomedics (IMMU) Reaches New 12-Month High at $14.57” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/24/immunomedics-immu-reaches-new-12-month-high-at-14-57.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

What are top analysts saying about Immunomedics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immunomedics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit